Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Treg and Teff Cell Dose Optimization in Double UCB Transplant
NCT01163201Phase 2Withdrawn
- Sponsor
- Masonic Cancer Center
- Start
- Jan 2014
- Primary completion
- Jan 2015
- Modality
- Allogeneic CAR-T, Tumor-Infiltrating Lymphocytes (TILs), TCR-Engineered T Cells
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of regulatory T cells injection in hematologic malignancy, acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL) and 14 more, sponsored by Masonic Cancer Center. Primary endpoint: Optimal Cell Dose Mixture at Day 0. Planned start Jan 2014; status: withdrawn.
02
Drugs
regulatory T cells injection
03
Conditions
hematologic malignancyacute myeloid leukemia (AML)acute lymphoblastic leukemia (ALL)chronic myelogenous leukemia (CML)myelodysplastic syndrome, refractory anemia with excess blasts (RAEB)
Beyond the preview
Go deeper on NCT01163201.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01163201.